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Background: There is limited evidence to support the efficacy of current pharmaceutical 
agents in reducing the risk of hip fracture in older postmenopausal women with established 
osteoporosis.
Objective: To clarify the efficacy of risedronate in reducing the risk of hip fracture in elderly 
postmenopausal women aged 70 years with established osteoporosis, i.e., those with bone 
mineral density-defined osteoporosis and a prevalent vertebral fracture.
Methods: Post hoc analysis of the Hip Intervention Program (HIP) study, a randomized 
controlled trial comparing risedronate with placebo for reducing the risk of hip fracture in 
elderly women. Women aged 70 to 100 years with established osteoporosis (baseline femoral 
neck T-score  −2.5 and  1 prior vertebral fracture) were included. The main outcome measure 
was 3-year hip fracture incidence in the risedronate and placebo groups.
Results: A total of 1656 women met the inclusion criteria. After 3 years, hip fracture had 
occurred in 3.8% of risedronate-treated patients and 7.4% of placebo-treated patients (relative 
risk 0.54; 95% confidence interval 0.32–0.91; P = 0.019).
Conclusion: Risedronate significantly reduced the risk of hip fracture in women aged up to 
100 years with established osteoporosis.
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Introduction
Non-vertebral fractures are the most frequent fractures in patients who present with a 
clinical fracture at an emergency unit.1 Of these, hip fractures are the most devastating 
because they lead to serious disability, an increased risk of mortality, and a high 
socioeconomic cost.2 Only two studies have studied prevention of hip fracture as a 
primary end point: the Hip Intervention Program (HIP);3 and, more recently, the Health 
Outcomes and Reduced Incidence with Zoledronic acid ONce yearly Pivotal Fracture 
Trial (HORIZON-PFT).4 Risedronate reduced the risk of hip fractures by 30%3 and 
zoledronic acid by 41%.4 In a subgroup analysis of the HIP study, risedronate had 
no effect on hip fracture in women aged 80 years, but 58% of these patients were 
selected exclusively on the basis of them having 1 fall risk3 and only 16% had 
documented bone mineral density (BMD) or vertebral fracture status, indicating that 
selection of patients occurred mainly on the basis of fall risks alone. In a post hoc 
analysis of the HIP and Vertebral Efficacy with Risedronate Therapy (VERT) studies 
in women aged 80 years with osteoporosis or at least one prevalent vertebral fracture, 
risedronate reduced the risk of vertebral fractures,5 indicating that fracture prevention 
with risedronate is possible in the very elderly with bone-related fracture risks.Clinical Interventions in Aging 2009:4 446
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The incidence of hip fractures in women increases 
exponentially with age and is related to bone- and fall-related 
risks,6 but 66% of hip fractures in women occur before the age 
of 85 years.7 We studied the effect of risedronate on hip frac-
tures in women older than 70 years and aged up to 100 years 
with well-documented bone-related fracture risks, and tested 
the hypothesis of hip fracture prevention with risedronate 
in an available group of patients, which included the very 
elderly, with established osteoporosis from the HIP study.
Methods
study included in the analysis
The present analysis focused on a subgroup of the 
intention-to-treat (ITT) population from the HIP study 
comprising women aged 70 to 100 years with National 
Health and Nutrition Examination Survey (NHANES) III 
defined baseline femoral neck T-score of  −2.5 and at 
least one prior vertebral fracture consistent with the World 
Health Organization/International Osteoporosis Foundation 
criteria for established postmenopausal osteoporosis.8,9 As in 
the original analysis, time-to-first fracture methodology 
was used to estimate the 3-year hip fracture incidence and 
observed treatment efficacy in women randomized to 2.5 mg 
or 5.0 mg risedronate, or to placebo. Hip fracture incidence 
in the placebo group in our analysis and in the overall ITT 
population was compared in order to further delineate the 
efficacy of risedronate in the subgroup of women eligible 
for inclusion in our study.
The HIP study3 was a 3-year, double-blind, placebo-
controlled,  randomized  study  conducted  between 
November 1993 and April 1998 at 183 study centers in 
Europe, North America, New Zealand, and Australia. Ambu-
latory postmenopausal women were enrolled in two groups: 
(1) women aged 70 to 79 years on the basis of low BMD; and 
(2) women aged 80 years on the basis of low BMD (16% 
of the group population) or the presence of 1 non-skeletal, 
fall-related risk factors (58% of the group population) which, 
at the time, were documented to predispose the patient to 
osteoporosis-related hip fracture (see Table 1).3,10,11 These risk 
factors included difficulty standing from a sitting position; 
poor tandem gait; fall-related injury during the previous year; 
psychomotor score of 5 on the Clifton Modified Gibson 
Spiral Maze Test;11 current smoking or smoking during the 
previous 5 years; maternal history of hip fracture; previous 
hip fracture; and/or hip-axis length of 11.1 cm.
Women were randomized to daily treatment with 2.5 mg 
or 5.0 mg risedronate, or an identical-appearing placebo. 
All women received 1000 mg elemental calcium daily, and 
those with baseline serum 25-hydroxyvitamin D  40 nmol/L 
were given vitamin D  500 IU daily.
All women underwent physical examination at the 
beginning and end of the study. Information about adverse 
events was collected at regular intervals during the study. 
The study design, patients enrolled, and methods have 
been described in detail previously.3
Measurement of efficacy
The primary end point of the HIP study was the incidence of 
radiographically confirmed hip fractures. Baseline vertebral 
fracture status was determined by examination of spinal 
radiographs according to published methods.12
statistical analysis
The HIP study ITT population comprised 9331 women 
who had received 1 dose of either risedronate or placebo. 
Kaplan-Meier survival (time-to-first fracture) estimates 
were used to calculate the incidence of hip fracture, and the 
log-rank test was used to assess the significance of differ-
ences between the treatment groups. Proportional-hazards 
analysis was used to estimate the relative risk (with the 95% 
confidence interval [CI]) of hip fracture in the risedronate 
group compared with the placebo group. All tests were 
two-sided.
Results
Out of 9331 women enrolled in the original study, 6876 had 
available and evaluable vertebral fracture status of which 4702 
had low BMD. A total of 1656 women had low BMD and 
at least one prevalent vertebral fracture and were, therefore, 
eligible for analysis. Of these, 1090 received risedronate and 
566 received placebo (see Figure 1). Baseline characteristics 
Table 1 Criteria for enrollment in the hIP study3
Age 70–79 years Age  80 years
Femoral neck T-scorea  −4
or
Femoral neck T-scorea  −3 plus 1  
clinical risk factor for hip fractureb
Femoral neck T-scorea  −4
or
Femoral-neck T-scorea  −3 plus 
hip-axis length 11.1 cm
or
1 non-skeletal risk factor for 
hip fractureb
aBone mineral density at the femoral neck more than 4 or 3, as applicable, standard 
deviations below the mean peak value in young adults. For purposes of enrollment, 
femoral neck T-scores were calculated according to the manufacturer’s reference 
data base for the densitometer.   The femoral-neck T-scores at baseline were later 
recalculated according to reference data from nhAnes III.10
bDifficulty standing from a sitting position; poor tandem gait; fall-related injury during 
the previous year; psychomotor score of 5 on the Clifton Modified Gibson Spiral 
Maze   Test;11 current smoking or smoking during the previous 5 years; maternal 
history of hip fracture; previous hip fracture; and/or hip-axis length of 11.1 cm.Clinical Interventions in Aging 2009:4 447
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of the placebo and treatment groups were similar, and were 
comparable to the baseline characteristics of the original ITT 
population (Table 2).
Hip fracture occurred in 7.4% of women receiving 
placebo in our study compared with 3.9% of women receiving 
placebo in the ITT population of the HIP study, confirming 
that women with established osteoporosis are at higher risk 
of fracture than are those of the same age who do not have 
established osteoporosis.
In women with established osteoporosis, the incidence 
of hip fracture in those receiving risedronate was 3.8% 
compared with 7.4% in women receiving placebo. Compared 
with placebo, risedronate 2.5 mg or 5.0 mg once daily reduced 
the risk of hip fracture by 46% (relative risk [RR] 0.54; 95% 
CI 0.32–0.91; P = 0.019) in women aged 70–100 years with 
established osteoporosis (Table 3).3 This was a numerical 
larger risk reduction than that found in the overall ITT 
population from the HIP study (RR 0.7; 95% CI 0.6–0.9; 
P = 0.02) (Table 3).
In an analysis of the women included in our study, the 
proportion of women who had any adverse event, who had 
a serious adverse event, or who withdrew because of an 
adverse event was similar regardless of treatment group. The 
incidence of death among women in our study was similar 
regardless of treatment group.
Discussion
Our analysis represents the first and only evidence to suggest 
that an oral bisphosphonate is effective in reducing the 
risk of hip fractures in elderly women aged up to 100 years. 
The HIP study demonstrated that, compared with placebo, 
risedronate significantly reduced the risk of hip fracture 
in the overall ITT population by 30% (RR 0.7; 95% 
CI 0.6–0.9; P = 0.02).3 In women aged 70–79 years with 
low BMD, risedronate reduced the risk of hip fracture by 
40% (RR 0.6; 95% CI 0.4–0.9; P = 0.009), and in those 
with low BMD and a prevalent vertebral fracture by 60% 
(RR 0.4; 95% CI 0.2–0.8; P = 0.003). In contrast, active 
treatment did not significantly reduce the incidence 
of hip fracture compared with placebo among women 
aged 80 years (RR 0.8; 95% CI 0.6–1.2; P = 0.35). 
However, most (58%) of the women aged 80 years 
were recruited solely according to the presence of at 
least one non-skeletal risk factor, and only a minority 
(16%) were recruited on the basis of a T-score  −4 at 
the femoral neck (manufacturer’s reference database for 
the densitometer). The present study demonstrates that 
risedronate is efficacious in older postmenopausal women 
with established osteoporosis, reducing the risk of hip 
fracture by 46% compared with placebo. This significant 
reduction in fracture risk occurred in a high-risk group of 
patients, with a placebo fracture incidence of 7.4% (almost 
double that of patients receiving placebo in the overall ITT 
population [3.9%]).
The HORIZON-PFT is the only other study to demonstrate 
the efficacy treatment with a bisphosphonate (zoledronic acid 
infused once yearly) in reducing the risk of hip fracture as a 
primary end point in older (aged 65–89 years, mean 73) post-
menopausal women. Over 3-years, hip fracture incidence was 
reduced from 2.5% in the placebo group to 1.4% with annual 






6876 women for whom 
vertebral-fracture status 
was known 
4702 of which had low 
BMD
1656 women had low BMD 
and ≥  1 prevalent vertebral 
fracture
9331 women in the 
HIP ITT Study population 
Figure 1 study population.
Abbreviations: BMD, bone mineral density; ITT, intention to treat.
Table 2 Demographic and baseline characteristics







  Mean ± sD 77 ± 5 77 ± 5
  80 years, n (%) 122 (22) 250 (23)
Time since menopause,  
years, mean ± sD
31 ± 9 31 ± 9
height, cm, mean ± sD 155.1 ± 7.2 154.6 ± 7.0
Weight, kg, mean ± sD 58.8 ± 10.6 58.1 ± 10.4
aFemoral neck T-score nhAnes III  −2.5 and  1 prevalent vertebral fractures.
Abbreviation: sD, standard deviation.Clinical Interventions in Aging 2009:4 448
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It has also been documented that drug treatment aimed 
at improving the bone component of fracture risk is effec-
tive when patients have well-defined bone-related risk. For 
example, in the Fracture Intervention Trial (FIT-1), in women 
aged 55 to 81 years with low BMD and at least one vertebral 
fracture, alendronate was shown to significantly reduce the 
risk of hip fracture, which was captured as a secondary end 
point in the prospective study.13 However, in the FIT-2 trial, 
in patients with low BMD and without baseline vertebral 
fracture, alendronate was not shown to reduce the risk of 
hip fractures.14 In the Treatment of Peripheral Osteoporosis 
(TROPOS) study, strontium ranelate did not significantly 
reduce the incidence of hip fracture in the overall ITT popu-
lation at 3 years (RR 0.85; 95% CI 0.61–1.19; P = 0.333).15 
In a post hoc analysis, strontium ranelate was shown to 
significantly reduce the risk of hip fractures at 3-years 
compared with placebo in a high fracture-risk subgroup of 
women aged 74 years with a T-score of  −3.0 (−2.4 
NHANES III) (RR 0.64; 95% CI 0.41–1.00; P = 0.046).15 
A study to demonstrate the efficacy of ibandronate included 
women aged 55-80 years.16 Ibandronate was not shown to 
reduce non-vertebral fractures in the overall study popula-
tion but did demonstrate fracture risk reduction in a post hoc 
analysis in a high-risk group of patients with low BMD.16 
Hip fractures were not assessed separately. Taken together, 
these findings support the hypothesis that drug treatment 
which focuses on the bone component of fracture risk is more 
effective if bone-related risks are present and documented.
In addition to addressing the bone component of fracture 
risk, it is worth noting that most hip fractures result from a 
fall or stumble,17 and an older individual’s increased fracture 
risk reflects not only their reduced bone strength, but also an 
increased propensity to fall and a loss of protective reflexes.1,18 
Some authors have, therefore, suggested that the focus of 
fracture prevention should be shifted from the treatment 
of osteoporosis to the prevention of falls.19 In the USA, the 
Surgeon General guideline on fracture prevention advises an 
integrated approach to prevent fractures, including lifestyle 
advice, fall prevention advice, and drug treatment to prevent 
fractures when appropriate.20 However, this should be in addi-
tion to, rather than instead of, osteoporosis treatment.21 The 
hypothesis that a combined bone- and fall-related approach 
reduces fracture risk more than when only bone-directed drug 
treatment is given, still needs to be documented. Although 
there are some data demonstrating the efficacy of focused 
or multifactorial fall-prevention programs on fall risk,22 
none have demonstrated an effect on fracture prevention.23
Our study provides evidence for the efficacy of an oral 
bisphosphonate in a group of older postmenopausal women 
at highest risk of fracture. However, there are several 
limitations to be considered. As 98% of women in the HIP 
study were white, our results do not necessarily apply to 
older postmenopausal women with severe osteoporosis in 
other racial groups. Our study also shares the limitations 
of all subgroup analyses, especially when performed post 
hoc, including diminished power to detect real differences, 
increase in the variance around the mean estimate, and 
increasing statistical likelihood of a false finding.24 These 
limitations are, however, mitigated by the fact that hip fracture 
prevention was the primary end point in the HIP study and 
the inclusion of a large, clearly defined subgroup of the ITT 
population in our analysis.
The findings of this analysis show that risedronate is effective 
in reducing the risk of hip fracture in elderly women aged up 
to 100 years with established osteoporosis. It is also acknowl-
edged, particularly in the elderly, that falls are associated with 
an increased fracture risk. However, it remains to be shown 
that the addition of fall prevention measures to bone-directed 
therapy will have further benefit for fracture prevention.
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